AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUREN PHARMACEUTICALS LTD

12.360

-0.230-1.83%

Volume:153.73K

Turnover:1.90M

Market Cap:1.57B

PE:11.38

High:12.500

Open:12.320

Low:12.250

Close:12.590

Loading ...

Overview Company News Filings

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Simply Wall St.

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Simply Wall St.

Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher

Here are the top 10 ASX 200 shares today

Why Block, GQG, Neuren, and Sigma shares are racing higher today

Neuren Pharmaceuticals Says Daybue Year-to-Date Net Sales Exceeds $250 Million Full-Year Threshold; Shares Up 7%

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Sees FY24 Income A$216 - 218 Mln

BUZZ-Australia's Neuren Pharmaceuticals hits 1-month high on upbeat sales

Neuren Pharmaceuticals Ltd - Sees FY2024 Income a$216 - 218 Mln

THOMSON REUTERS

Collins Foods And 2 Other ASX Undervalued Small Caps With Insider Buying

Simply Wall St.

ASX Market Close: IT & Utilities lead the bourse higher as US votes counted | November 6, 2024

The Market Herald

Why Brainchip, Cooper Energy, Core Lithium, and Neuren shares are roaring higher today

Neuren Pharmaceuticals' US Partner to Sell Rare Pediatric Disease Priority Review Voucher for $150 Million; Shares Up 6%

MT Newswires Live

BRIEF-Neuren Pharmaceuticals Says Co To Get $150M from Acadia Pharma's Pediatric Voucher Sale

ASX 200 healthcare stock rockets on $75 million news

Neuren Pharmaceuticals - ACADIA Pharmaceuticals Entered Into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for US$150M

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NEU.AU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NEU.AU"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","market":"AU","secType":"STK","nameCN":"NEUREN PHARMACEUTICALS LTD","latestPrice":12.36,"timestamp":1741310573507,"preClose":12.59,"halted":0,"volume":153725,"delay":0,"changeRate":-0.018268,"change":-0.23,"floatShares":110014206,"shares":127012624,"eps":1.086099,"lyrEps":1.111713,"pbRate":4.31,"amount":1899770,"amplitude":0.019857,"volumeRatio":0.454484,"dividePrice":0,"prevYearClose":12.5,"fiveDayClose":13.23,"twentyDayClose":14.02},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NEU.AU\",,,,,undefined,":{"symbol":"NEU.AU","floatShares":110014206,"roa":"34.05%","roe":"49.92%","lyrEps":1.111713,"volumeRatio":0.454484,"shares":127012624,"dividePrice":0,"high":12.5,"amplitude":0.019857,"preClose":12.59,"low":12.25,"week52Low":10.9,"pbRate":"4.31","psRate":"7.24","week52High":24,"institutionHeld":0,"latestPrice":12.36,"committee":-0.316498,"eps":1.086099,"divideRate":0,"volume":153725,"delay":0,"ttmEps":1.086099,"open":12.32,"prevYearClose":12.5,"prevWeekClose":13.23,"prevMonthClose":13.23,"prevQuarterClose":12.5,"fiveDayClose":13.23,"twentyDayClose":14.02,"sixtyDayClose":12.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NEU.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740697200000,"name":null,"time":"","dateTimestamp":1740661200000,"actualEps":null},{"market":"AU","date":"2024-02-29","symbol":"NEU.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1709125200000,"reportTimeType":"","actualEps":null},{"date":"2023-08-28","symbol":"NEU.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1693180800000,"name":null,"time":"","dateTimestamp":1693144800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NEU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NEU.AU\",pageSize:16,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2482168827","title":"New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)","url":"https://stock-news.laohu8.com/highlight/detail?id=2482168827","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482168827?lang=en_us&edition=fundamental","pubTime":"2024-11-12 04:14","pubTimestamp":1731356063,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Limited ( ASX:NEU ) shareholders will have a reason to smile today, with the analysts making...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/new-forecasts-heres-what-analysts-think-the-future-holds-for-260","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7508","NEU.AU","NEU","BK4109","BK7096"],"gpt_icon":1},{"id":"2482462018","title":"Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up","url":"https://stock-news.laohu8.com/highlight/detail?id=2482462018","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482462018?lang=en_us&edition=fundamental","pubTime":"2024-11-09 04:00","pubTimestamp":1731096058,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals Limited ( ASX:NEU ) shares have had a really impressive month, gaining 26% after a shaky period...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-neu/neuren-pharmaceuticals-shares/news/neuren-pharmaceuticals-limiteds-asxneu-shares-climb-26-but-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NEU.AU","BK4109","NEU","BK7096","BK7508"],"gpt_icon":0},{"id":"2481873167","title":"Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2481873167","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481873167?lang=en_us&edition=fundamental","pubTime":"2024-11-08 10:13","pubTimestamp":1731032010,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is having a great finish to the week. In afternoon trade, the benchmark index is up 0.9% to 8,299.4 points. Four ASX shares that are rising more than most are listed bel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/08/why-imugene-neuren-sigma-and-smartgroup-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","SIQ.AU","BK7057","SIG.AU","BK7096","NEU.AU","BK7103","XJO.AU","BK7067","IMU.AU"],"gpt_icon":0},{"id":"2481603947","title":"Here are the top 10 ASX 200 shares today","url":"https://stock-news.laohu8.com/highlight/detail?id=2481603947","media":"MotleyFool","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481603947?lang=en_us&edition=fundamental","pubTime":"2024-11-07 14:10","pubTimestamp":1730959812,"startTime":"0","endTime":"0","summary":"It was a wild session for the S&P/ASX 200 Index (ASX: XJO) this Thursday as investors continued to digest the impact of this week's American elections. After several stints in both positive and negati","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/07/here-are-the-top-10-asx-200-shares-today-527/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BSL.AU","XJO.AU","BK7081","NEU.AU","BK7093","BK7078","BK7096","BK7034","BK7103","BK7503","JLG.AU","CPU.AU","WOR.AU","AAI.AU","BK7157","CCP.AU","BK7033","BK7055","BK7129","TAH.AU","BK7108","BK7508","QBE.AU","SIG.AU"],"gpt_icon":1},{"id":"2481915348","title":"Why Block, GQG, Neuren, and Sigma shares are racing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2481915348","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481915348?lang=en_us&edition=fundamental","pubTime":"2024-11-07 11:01","pubTimestamp":1730948499,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) has failed to follow Wall Street's stunning lead and has dropped into the red. In afternoon trade, the benchmark index is down 0.2% to 8,182.9 points. Four ASX shares t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/07/why-block-gqg-neuren-and-sigma-shares-are-racing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IE0002270589.USD","IE00B7SZLL34.SGD","LU1861559042.SGD","BK4106","BK7096","GQG.AU","BK7103","BK7062","XJO.AU","BK7158","SQ2.AU","BK4588","BK4503","IE00B19Z3581.USD","BK4554","BK4585","BK4227","BK4581","IE00B19Z3B42.SGD","BK7033","NEU.AU","BK4551","IE00BHPRN162.USD","BK7508","LU1861558580.USD","SIG.AU","BK4528"],"gpt_icon":1},{"id":"2481399725","title":"Neuren Pharmaceuticals Says Daybue Year-to-Date Net Sales Exceeds $250 Million Full-Year Threshold; Shares Up 7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481399725","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481399725?lang=en_us&edition=fundamental","pubTime":"2024-11-07 10:25","pubTimestamp":1730946310,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals (ASX:NEU) said net sales of oral Rett syndrome treatment Daybue from January to September exceeded the full-year threshold of $250 million for the company to earn the first sale","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NEU.AU"],"gpt_icon":1},{"id":"2481996982","title":"BRIEF-Neuren Pharmaceuticals Sees FY24 Income A$216 - 218 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2481996982","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481996982?lang=en_us&edition=fundamental","pubTime":"2024-11-07 09:17","pubTimestamp":1730942250,"startTime":"0","endTime":"0","summary":"BRIEF-Neuren Pharmaceuticals Sees FY24 Income A$216 - 218 MlnNov 7 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:SEES FY2024 INCOME A$216 - 218 MILLIONFurther company coverage: NEU.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3MD1TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2481088995","title":"BUZZ-Australia's Neuren Pharmaceuticals hits 1-month high on upbeat sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2481088995","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481088995?lang=en_us&edition=fundamental","pubTime":"2024-11-07 09:05","pubTimestamp":1730941548,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neuren Pharmaceuticals hits 1-month high on upbeat sales** Shares of Neuren Pharmaceuticals NEU.AX rise as much as 8.1% to A$14.350, their highest since Oct. 7** Biopharmaceutical reports Rett syndrome drug Daybue's 9 months net sales exceeded full-year threshold of $250 mln** Co sees full-year income to be in the range of A$216 mln to A$218 mln ** Stock down 43.1% YTD as of 0046 GMT  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nL4N3ME025:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NEU.AU"],"gpt_icon":1},{"id":"2481964375","title":"Neuren Pharmaceuticals Ltd - Sees FY2024 Income a$216 - 218 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2481964375","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481964375?lang=en_us&edition=fundamental","pubTime":"2024-11-07 07:20","pubTimestamp":1730935218,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241106:nFWN3MD1TV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","NEU.AU","BK7096"],"gpt_icon":0},{"id":"2481620569","title":"Collins Foods And 2 Other ASX Undervalued Small Caps With Insider Buying","url":"https://stock-news.laohu8.com/highlight/detail?id=2481620569","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481620569?lang=en_us&edition=fundamental","pubTime":"2024-11-06 17:06","pubTimestamp":1730883999,"startTime":"0","endTime":"0","summary":"Recent movements in the Australian market have seen the ASX200 rise by 0.83%, with all sectors gaining ground, notably led by IT and Financials. As markets closely monitor ongoing developments such as the US election, investors are increasingly focused on identifying opportunities within small-cap stocks that may offer potential value amidst broader economic shifts. In this context, understanding what constitutes a promising stock—such as solid fundamentals and strategic insider activities—can be crucial for navigating current market conditions effectively.Top 10 Undervalued Small Caps With Insider Buying In Australia. Click here to see the full list of 24 stocks from our Undervalued ASX Small Caps With Insider Buying screener.Operations: The company generates revenue primarily from wholesale computer peripherals, with recent figures reaching A$2.24 billion. Its gross profit margin h","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Lvd_lXQD0CnLIwypMB0Chg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5bcbcb810206bcc5d4f98bf0187f8a6c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Lvd_lXQD0CnLIwypMB0Chg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5bcbcb810206bcc5d4f98bf0187f8a6c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/collins-foods-2-other-asx-090639237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7068","BK7508","XKO.AU","NEU.AU","BK7137","XAO.AU","XJO.AU","CKF.AU","BK7096","DDR.AU"],"gpt_icon":1},{"id":"2481765646","title":"ASX Market Close: IT & Utilities lead the bourse higher as US votes counted | November 6, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2481765646","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481765646?lang=en_us&edition=fundamental","pubTime":"2024-11-06 14:22","pubTimestamp":1730874120,"startTime":"0","endTime":"0","summary":"The ASX200 has been up 0.83% at 8199 points.Counting in the US election continues and markets are eagerly watching the results trickle in and are reacting accordingly.All sectors have gained ground and the IT sector has been the best performer, up 1.9%, followed by Financials, up 1.6%, and Discretionary, up 1.54%.Cooper Energy  closed up 6.06% on release of an update on FY25 guidance. It revealed that it is increasing its production guidance and says its primarily driven by improved performance at the Orbost Gas Processing Plant.BENZ Mining closed up 11.54% after buying WA gold projects offSpartan Resources . Benz is to snatch up the Glenburgh and Mt Egerton gold projects from Spartan; in exchange, Spartan will become a 15% shareholder in Benz.Great Boulder Resourcesclosed down 2.22% on reported progress in its exploration activities at the Side Well Gold Project, located near Meekatharra in WA. Recent reverse circulation drilling at the Mulga Bill prospect has identified subvertical g","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-close-it-utilities-lead-the-bourse-higher-as-us-votes-counted-november-6-2024-2024-11-06/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["LU2065171311.SGD","ACAD","BK7002","LU2065169927.USD","LU2065171402.SGD","BK7503","BK7508","COE.AU","LU2065170008.USD","BK4139","SPAQ.U","BK7104","NEU.AU","BK7096","BNZ.AU","BGL.AU","BK7504","DHG.AU","BK7142","SPR.AU","GBR.AU","BK7095"],"gpt_icon":1},{"id":"2481615653","title":"Why Brainchip, Cooper Energy, Core Lithium, and Neuren shares are roaring higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2481615653","media":"MotleyFool","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481615653?lang=en_us&edition=fundamental","pubTime":"2024-11-06 11:30","pubTimestamp":1730863840,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is on course to record a strong gain. At the time of writing, the benchmark index is up 0.9% to 8,202.6 points. Four ASX shares that are rising more","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/06/why-brainchip-cooper-energy-core-lithium-and-neuren-shares-are-roaring-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7142","BK7016","BK7508","ACAD","LU2065171402.SGD","LU2065171311.SGD","NEU.AU","XJO.AU","BK7096","BK7507","COE.AU","CXO.AU","BK4139","BK7504","BRN.AU","LU2065170008.USD","BK7095","LU2065169927.USD"],"gpt_icon":1},{"id":"2481696635","title":"Neuren Pharmaceuticals' US Partner to Sell Rare Pediatric Disease Priority Review Voucher for $150 Million; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2481696635","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481696635?lang=en_us&edition=fundamental","pubTime":"2024-11-06 09:48","pubTimestamp":1730857736,"startTime":"0","endTime":"0","summary":"Neuren Pharmaceuticals  said its partner, Nasdaq-listed Acadia Pharmaceuticals, agreed to sell the Rare Pediatric Disease Priority Review Voucher  for $150 million, according to a Wednesday filing with the Australian bourse.The company is entitled to one-third of the proceeds of the sale under its license agreement with Acadia, according to the filing.The PRV was granted by the US Food and Drug Administration after the approval of Daybue for Rett syndrome treatment, the filing said.Neuren Pharmaceuticals shares rose past 6% in midday trade Wednesday.Price : $13.04, Change: $+0.77, Percent Change: +6.28%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUD","LU0426412945.USD","LU2238339852.HKD","BK7508","NEU.AU","LU0994945656.USD","LU1043141123.HKD","BK7096","LU0345774631.USD","LU0426417589.USD","BK4125"],"gpt_icon":0},{"id":"2481983526","title":"BRIEF-Neuren Pharmaceuticals Says Co To Get $150M from Acadia Pharma's Pediatric Voucher Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2481983526","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481983526?lang=en_us&edition=fundamental","pubTime":"2024-11-06 09:13","pubTimestamp":1730855581,"startTime":"0","endTime":"0","summary":"Nov 6  - Neuren Pharmaceuticals   :   * ACADIA PHARMACEUTICALS ENTERED INTO AGREEMENT TO SELL RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER FOR US$150M   * ENTITLED TO RECEIVE ONE-THIRD OF NET PROCEEDS FROM DEAL TO SELL RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHERFurther company coverage:    ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","NEU.AU","BK7508"],"gpt_icon":0},{"id":"2481866779","title":"ASX 200 healthcare stock rockets on $75 million news","url":"https://stock-news.laohu8.com/highlight/detail?id=2481866779","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481866779?lang=en_us&edition=fundamental","pubTime":"2024-11-06 08:41","pubTimestamp":1730853685,"startTime":"0","endTime":"0","summary":"ASX healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU) has surged in early trade on Wednesday after a company update.  Shares in the biopharma company currently fetch $12.95 apiece, nearly 6% high","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/06/asx-200-healthcare-stock-rockets-on-75-million-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7096","NEU.AU"],"gpt_icon":0},{"id":"2481439650","title":"Neuren Pharmaceuticals  - ACADIA Pharmaceuticals Entered Into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for US$150M","url":"https://stock-news.laohu8.com/highlight/detail?id=2481439650","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481439650?lang=en_us&edition=fundamental","pubTime":"2024-11-06 06:26","pubTimestamp":1730845598,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241105:nFWN3MC188:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NEU.AU","BK7096","BK7508"],"gpt_icon":0}],"pageSize":16,"totalPage":7,"pageCount":5,"totalSize":106}]}}